SCHEMBL7606295

SCHEMBL7606295

CCCCCN1C(=O)C(C)Oc2cc(C)c(C)cc21

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 4/20 0.42
THRB P10828 1/20 0.41
SCN9A Q15858 1/20 0.40
REN P00797 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGS1 P23219 3/20 0.39
PTGS2 P35354 3/20 0.39
MGLL Q99685 2/20 0.39
FAAH O00519 1/20 0.39
CYP1A2 P05177 1/20 0.38
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7602306 0.96 TSHR (0.47) TSHRNPSR1ALDH1A1THRBREN
SCHEMBL7606445 0.91 TSHR (0.42) TSHRNPSR1ALDH1A1THRBSCN9A
SCHEMBL7606304 0.91 TSHR (0.42) TSHRNPSR1ALDH1A1THRBSCN9A
SCHEMBL7603093 0.87 TSHR (0.43) TSHRNPSR1ALDH1A1THRBREN
SCHEMBL7604336 0.87 TSHR (0.43) TSHRNPSR1ALDH1A1THRBREN
SCHEMBL5987076 0.85 REN (0.49) TSHRNPSR1ALDH1A1THRBREN
SCHEMBL7636421 0.83 REN (0.53) TSHRNPSR1ALDH1A1THRBREN
SCHEMBL5985698 0.77 REN (0.46) TSHRNPSR1ALDH1A1THRBREN
SCHEMBL5987063 0.77 REN (0.46) TSHRNPSR1ALDH1A1THRBREN
SCHEMBL12361721 0.77 TSHR (0.43) TSHRNPSR1ALDH1A1THRBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US disclosed
US-8389511-B2 Bicyclic heterocyclic derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 US disclosed
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE DAINIPPON SUMITOMO PHARMA CO. 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE REN, AGTR1, AGTR2 TSHR 772/4885NPSR1 536/4885ALDH1A1 288/4885
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 TSHR 1316/4885NPSR1 378/4885ALDH1A1 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.